The choroid is involved directly or indirectly in many pathological conditions such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS).
Objective:
The objective of this study was to investigate the association between retinal choroidal properties and the pathology of AD by determining choroidal thickness, hippocampus volume, cognitive functions, and plasma BACE1 activity.
Methods:
In this cross-sectional study, 37 patients with AD and 34 age-matched controls were included. Retinal choroidal thickness was measured via enhanced depth imaging optical coherence tomography. Hippocampal volume was measured via 3.0T MRI. Cognitive functions were evaluated using the Mini-Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog). Plasma BACE1 activity was analyzed using a fluorescence substrate-based plasma assay, and regression model were to analyze the data.
Results:
Retinal choroidal thickness was significantly thinner in the AD group than in the control group [(114.81±81.30) μm versus (233.79±38.29) μm, p < 0.05]. Multivariable regression analysis indicated that the ADAS-cog scores (β=–0.772, p = 0.000) and age (β=–0.176, p = 0.015) were independently associated with choroidal thickness. The logistic regression model revealed that the subfoveal choroidal thickness was a significant predictor for AD (OR = 0.984, 95% CI: 0.972–0.997).
Conclusion:
There was a general tendency of choroid thinning as the cognitive function declined. Although choroidal thickness was not a potential indicator for early stage AD, it was valuable in monitoring AD progression.
LimJK, LiQX, HeZ, VingrysAJ, WongVH, CurrierN, MullenJ, BuiBV, NguyenCT (2016) The eye as a biomarker for Alzheimer’s disease. Front Neurosci10, 536.
2.
TzekovR, MullanM (2014) Vision function abnormalities in Alzheimer disease. Surv Ophthalmol59, 414–433.
3.
SivakJM (2013) The aging eye: Common degenerative mechanisms between the Alzheimer’s brain and retinal disease. Invest Ophthalmol Vis Sci54, 871–880.
4.
GhisoJA, DoudevskiI, RitchR, RostagnoAA (2013) Alzheimer’s disease and glaucoma: Mechanistic similarities and differences. J Glaucoma22(Suppl 5), S36–S38.
5.
KaarnirantaK, SalminenA, HaapasaloA, SoininenH, HiltunenM (2011) Age-related macular degeneration (AMD): Alzheimer’s disease in the eye?J Alzheimers Dis24, 615–631.
6.
WangM, ZhuY, ShiZ, LiC, ShenY (2015) Meta-analysis of the relationship of peripheral retinal nerve fiber layer thickness to Alzheimer’s disease and mild cognitive impairment. Shanghai Arch Psychiatry27, 263–279.
7.
LeeMJ, AbrahamAG, SwenorBK, SharrettAR, RamuluPY (2018) Application of optical coherence tomography in the detection and classification of cognitive decline. J Curr Glaucoma Pract12, 10–18.
8.
PattonN, AslamT, MacgillivrayT, PattieA, DearyIJ, DhillonB (2005) Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: A rationale based on homology between cerebral and retinal microvasculatures. J Anat206, 319–348.
9.
KalariaRN, AkinyemiR, IharaM (2012) Does vascular pathology contribute to Alzheimer changes?J Neurol Sci322, 141–147.
10.
LaviersH, ZambarakjiH (2014) Enhanced depth imaging-OCT of the choroid: A review of the current literature. Graefes Arch Clin Exp Ophthalmol252, 1871–1883.
11.
GharbiyaM, TrebbastoniA, ParisiF, ManganielloS, CrucianiF, D’AntonioF, De VicoU, ImbrianoL, CampanelliA, De LenaC (2014) Choroidal thinning as a new finding in Alzheimer’s disease: Evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimers Dis40, 907–917.
12.
BayhanHA, AslanBS, CelikbilekA, TanikN, GurdalC (2015) Evaluation of the chorioretinal thickness changes in Alzheimer’s disease using spectral-domain optical coherence tomography. Clin Exp Ophthalmol43, 145–151.
13.
BulutM, YamanA, ErolMK, KurtulusF, ToslakD, DoganB, TurgutCD, KayaBE (2016) Choroidal thickness in patients with mild cognitive impairment and Alzheimer’s type dementia. J Ophthalmol2016, 7291257.
Di StasoF, CiancagliniM, AbdolrahimzadehS, D’ApolitoF, ScuderiG (2019) Optical coherence tomography of choroid in common neurological diseases. In Vivo33, 1403–1409.
16.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
Réglade-MeslinC, AnsteyKJ, MallerJJ (2006) Sex and symmetry differences in hippocampal volumetrics: Before and beyond the opening of the crus of the fornix. Hippocampus16, 80–90.
19.
XiongJ, LancasterJL, SzaboCA (2001) Amygdalar and hippocampal volumetry in control participants: Differences regarding handedness. Am J Neuroradiol22, 1342–1345.
20.
LeprouxF, CendesF, MelansonD, EthierR, EvansA, PetersT, AndermannF (1993) MRI of amygdala and hippocampus in temporal lobe epilepsy. J Comput Assist Tomogr17, 206–210.
21.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
22.
RosenWG, MohsRC, DavisKL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry141, 1356–1364.
23.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
24.
LovemanE, GreenC, KirbyJ, TakedaA, PicotJ, PayneE, CleggA (2006) The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess10, 1–160.
25.
LiJ, WuHM, ZhouRL, LiuGJ, DongBR (2008) Huperzine A for Alzheimer’s disease. Cochrane Database Syst Rev2, D5592.
ZhangZ, CuiJ, GaoF, LiY, ZhangG, LiuM, YanR, ShenY, LiR. (2019) Elevated cleavage of neuregulin-1 by beta-secretase 1 in plasma of schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry90, 161–168.
28.
ShenY, WangH, SunQ, YaoH, KeeganAP, MullanM, WilsonJ, ListaS, LeyheT, LaskeC, RujescuD, LeveyA, WallinA, BlennowK, LiR, HampelH (2018) Increased plasma beta-secretase 1 may predict conversion to Alzheimer’s disease dementia in individuals with mild cognitive impairment. Biol Psychiatry83, 447–455.
29.
MargolisR, SpaideRF (2009) A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol147, 811–815.
30.
IkunoY, KawaguchiK, NouchiT, YasunoY (2010) Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci51, 2173–2176.
31.
BarteselliG, ChhablaniJ, El-EmamS, WangH, ChuangJ, KozakI, ChengL, BartschDU, FreemanWR (2012) Choroidal volume variations with age, axial length, and sex in healthy subjects: A three-dimensional analysis. Ophthalmology119, 2572–2578.
32.
UsuiS, IkunoY, AkibaM, MarukoI, SekiryuT, NishidaK, IidaT (2012) Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects. Invest Ophthalmol Vis Sci53, 2300–2307.
33.
BlanksJC, TorigoeY, HintonDR, BlanksRH (1996) Retinal pathology in Alzheimer’s disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging17, 377–384.
34.
DavatzikosC, ResnickSM, WuX, ParmpiP, ClarkCM (2008) Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage41, 1220–1227.
35.
GerischerLM, FehlnerA, KobeT, PrehnK, AntonenkoD, GrittnerU, BraunJ, SackI, FloelA (2018) Combining viscoelasticity, diffusivity and volume of the hippocampus for the diagnosis of Alzheimer’s disease based on magnetic resonance imaging. Neuroimage Clin18, 485–493.
36.
DaweRJ, YuL, ArfanakisK, SchneiderJA, BennettDA, BoylePA (2020) Late-life cognitive decline is associated with hippocampal volume, above and beyond its associations with traditional neuropathologic indices. Alzheimers Dement16, 209–218.
37.
AndrieuS, SampaioC, VellasB, GordonW, European Task Force Group (2007) Disease-modifying trials in Alzheimer’s disease: A European task force consensus. Lancet Neurol6, 56–62.
38.
KandalepasPC, VassarR (2011) The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer’s disease. Alzheimers Res Ther3, 20.
39.
MoecharsD, LichtenthalerSF, BarãoS (2016) BACE1 Physiological functions may limit its use as therapeutic target for Alzheimer’s disease. Trends Neurosci39, 158–169.
40.
ChengX, HeP, LeeT, YaoH, LiR, ShenY (2014) High activities of BACE1 in brains with mild cognitive impairment. Am J Pathol184, 141–147.
41.
KoelschG (2017) BACE1 Function and inhibition: Implications of Intervention in the amyloid pathway of Alzheimer’s disease pathology. Molecules22, 1723.
42.
YanR, VassarR (2014) Targeting the beta secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol13, 319–329.
43.
YanXX, MaC, GaiWP, CaiH, LuoXG (2014) Can BACE1 inhibition mitigate early axonal pathology in neurological diseases?J Alzheimers Dis38, 705–718.
44.
KandalepasPC, VassarR (2014) The normal and pathologic roles of the Alzheimer’s beta-secretase, BACE1. Curr Alzheimer Res11, 441–449.
45.
BaiS, MaoM, TianL, YuY, ZengJ, OuyangK, YuL, LiL, WangD, DengX, WeiC, LuoY (2015) Calcium sensing receptor mediated the excessive generation of beta-amyloid peptide induced by hypoxia in vivo and in vitro. Biochem Biophys Res Commun459, 568–573.
46.
YangEJ, MahmoodU, KimH, ChoiM, ChoiY, LeeJP, ChoJY, HyunJW, KimYS, ChangMJ, KimHS (2018) Phloroglucinol ameliorates cognitive impairments by reducing the amyloid beta peptide burden and pro-inflammatory cytokines in the hippocampus of 5XFAD mice. Free Radic Biol Med126, 221–234.
